XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis

被引：0
|
作者：
Fanghui Ye
Zhenfang Liu
Aihua Tan
Ming Liao
Zengnan Mo
Xiaobo Yang
机构：
[1] Guangxi Medical University,Center for Genomic and Personalized Medicine
[2] Guangxi Medical University,Department of Hematology, The First Affiliated Hospital
[3] Guangxi Medical University,Department of Chemotherapy, The Affiliated Tumor Hospital
[4] Guangxi Medical University,Institute of Urology and Nephrology, The First Affiliated Hospital
[5] Guangxi Medical University,Department of Occupational Health and Environmental Health, School of Public Health
来源：
Cancer Chemotherapy and Pharmacology | 2013年 / 71卷
关键词：
Oxaliplatin; Colorectal cancer; Genetic polymorphisms;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：733 / 740
页数：7
相关论文
共 50 条
  • [1] XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis
    Ye, Fanghui
    Liu, Zhenfang
    Tan, Aihua
    Liao, Ming
    Mo, Zengnan
    Yang, Xiaobo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 733 - 740
  • [2] ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
    Zaanan, Aziz
    Dalban, Cecile
    Emile, Jean-Francois
    Blons, Helene
    Flejou, Jean-Francois
    Goumard, Claire
    Istanbullu, Melek
    Calmel, Claire
    Alhazmi, Khalid
    Validire, Pierre
    Louvet, Christophe
    de Gramont, Aimery
    Laurent-Puig, Pierre
    Taieb, Julien
    Praz, Francoise
    JOURNAL OF CANCER, 2014, 5 (06): : 425 - 432
  • [3] Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy
    Huang, Zhao-Hui
    Hua, Dong
    Du, Xiang
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (05) : 1001 - 1007
  • [4] Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy
    Zhao-Hui Huang
    Dong Hua
    Xiang Du
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 1001 - 1007
  • [5] XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis
    Zhang, Xin
    Jiang, Li-Peng
    Yin, Yu
    Wang, Ya-Di
    TUMOR BIOLOGY, 2014, 35 (06) : 5637 - 5645
  • [6] XRCC1 polymorphisms and risk of colorectal cancer: a meta-analysis
    Wang, Bin
    Wang, Dan
    Huang, Gang
    Zhang, Chao
    Xu, Dong-hua
    Zhou, Weiping
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2010, 25 (03) : 313 - 321
  • [7] XRCC1 polymorphisms and risk of colorectal cancer: a meta-analysis
    Bin Wang
    Dan Wang
    Gang Huang
    Chao Zhang
    Dong-hua Xu
    Weiping Zhou
    International Journal of Colorectal Disease, 2010, 25 : 313 - 321
  • [8] Genetic Polymorphism of XRCC1 Correlated with Response to Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer
    Lv, Hongying
    Li, Qicai
    Qiu, Wengsheng
    Xiang, Jinyu
    Wei, Hongjun
    Liang, Hua
    Sui, Aihua
    Liang, Jun
    PATHOLOGY & ONCOLOGY RESEARCH, 2012, 18 (04) : 1009 - 1014
  • [9] A meta-analysis on XRCC1 and XRCC3 polymorphisms and colorectal cancer risk
    Jiang, Zheng
    Li, Chunxiang
    Xu, Ye
    Cai, Sanjun
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2010, 25 (02) : 169 - 180
  • [10] A meta-analysis on XRCC1 and XRCC3 polymorphisms and colorectal cancer risk
    Zheng Jiang
    Chunxiang Li
    Ye Xu
    Sanjun Cai
    International Journal of Colorectal Disease, 2010, 25 : 169 - 180
12345